ArticleFrontiers in cellular and infection microbiology2026
Carbapenemase-directed therapy: optimizing antibiotic combinations against carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Given the limited therapeutic options for infections caused by carbapenem-resistant Methods: The Results: Among CZA-resistant KPC-CRKP isolates, combinations of CZA with β-lactams exhibited high synergy rates (79.7-86.5%). In PMB-resistant KPC-CRKP, PMB + CZA demonstrated substantially higher synergy rates (53.2%) than conventional PMB-carbapenem combinations (≤3.8%). Against NDM-CRKP, CZA + aztreonam (ATM) showed synergistic activity in 83.3% of isolates. Notably, in KN-CRKP, CZA + ATM produced synergistic or additive effects in all isolates, despite resistance to the individual agents. SBPI analysis further suggested substantial antimicrobial enhancement in some combinations classified as indifferent by FICI, including PMB + tigecycline (TGC). Conclusions: Carbapenemase profiles substantially influence the efficacy of combination therapies against CRKP. CZA-based combinations, particularly those combined with β-lactams or ATM, demonstrated favorable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.